The story of Viagra and its creator , copyright, presents a fascinating picture for cautious investors. While the iconic drug initially fueled enormous revenues , its exclusivity has lapsed , leading to competing versions flooding the landscape . This decline in pricing presents a significant challenge for copyright and any fund considering a large